T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival

BACKGROUND: In HER2-overexpressing breast cancer, accumulating preclinical evidences suggest that some chemotherapies, like trastuzumab, but also taxanes, are able to trigger a T helper 1 (Th1) anticancer immune response that contribute to treatment success. T helper 1 immune response is characteris...

Descripción completa

Detalles Bibliográficos
Autores principales: Ladoire, S, Arnould, L, Mignot, G, Apetoh, L, Rébé, C, Martin, F, Fumoleau, P, Coudert, B, Ghiringhelli, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172914/
https://www.ncbi.nlm.nih.gov/pubmed/21750556
http://dx.doi.org/10.1038/bjc.2011.261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172914/
https://www.ncbi.nlm.nih.gov/pubmed/21750556
http://dx.doi.org/10.1038/bjc.2011.261

Ejemplares similares